Legend Biotech is no longer a clinical-stage story waiting on a myeloma launch. The equity is now a test of whether a partnered commercial franchise can keep compounding after the first quarter of company-wide profit, or whether that print is a one-time mix of milestones, currency, and a still-concentrated product. CARVYKTI, the BCMA-directed CAR-T therapy co-commercialized with Janssen, is the entire economic engine. The market is pricing the name as if that engine is already mature and politically noisy rather than still expanding into earlier lines and new countries. That gap between a franchise that is still taking share and a tape that already treats the story as fully discovered is the investment debate.
The mid-year quarter flipped the income statement. Worldwide CARVYKTI net trade sales reached $657 million, a fifty percent lift from the year-ago period. Legend booked $326 million of collaboration revenue as its contractual half of those sales. Total revenue rose to $388 million. Reported net income was $33 million against a year-ago loss, helped by Janssen sales milestones and a collapse in unrealized currency losses. The mechanism sits in mix rather than in a new approval. Earlier-line use now dominates United States volume, the Ireland launch took the network to 348 authorized sites, and operating expense grew far slower than the top line.
The strongest objection is that the profit is thinner than the headline. Collaboration gross profit barely covers Legend's own research and selling spend once the Janssen milestones are stripped out, and the same quarter still consumed operating cash. Ying Huang stepped down as chief executive in late July with no permanent successor named, and Alan Bash, the CARVYKTI commercial lead, is running the company on an interim basis. A June underwritten sale of 7,700,000 American depositary shares raised about $212 million of net proceeds at a price well above the subsequent tape, which is the opposite of a confident re-rating.
The next several quarters resolve whether sequential CARVYKTI growth and earlier-line mix hold after the milestone pulse fades, and whether a permanent chief executive is named without a strategy reset. The LB2501 in-vivo program's first-in-human readout is the only near-term proof that the platform is more than a single marketed product.